Live Breaking News & Updates on Tofacitinib

Stay informed with the latest breaking news from Tofacitinib on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Tofacitinib and stay connected to the pulse of your community

Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

Findings from a novel study supports the JAK inhibitor tofacitinib as a potential first-line therapy for ASUC.

India , Ravi-shah , Tofacitinib , Ulcerative-colitis , Uc , Asuc , Tacos , Trial , Jak , Inhibitor , Data

Tofacitinib Leads to Improvement in Itch, Other Symptoms Among Psoriasis Patients with PsA

These data on the success of twice-daily, 5 and 10 mg doses of tofacitinib may help inform clinicians in their practice as well as the health community in general.

Paris , France-general- , France , International-psoriasis-council-herv , International-psoriasis-council , Itch-severity-item , Psoriasis-area , Severity-index , Hospital-anxiety , Depression-scale , Psoriasis

Tofacitinib as AA Treatment Has High Drug Survival Rates, Manageable Side Effects

A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.

Changsha , Hunan , China , Chinese , Drug-administration , Department-of-dermatology , Image-credit , Chinese-food , Tofacitinib , Alopecia-areata , Efficacy

hair grow: A commonly used arthritis medicine can cure baldness, shows a study

A recent study published in Indian Dermatology has found that tofacitinib, a drug commonly used for rheumatoid arthritis, has shown promising results in treating alopecia areata. The study revealed that 94.1% of the patients showed a complete or near-complete response to the medication. Additionally, 23.5% of the patients achieved complete hair growth within eight months of treatment.

Kabir-sardana , Scalp-hair-loss-assessment-tool , Hair-grow , Tofacitinib , Rheumatoid-arthritis , Alopecia-areata , Hair-loss , Treatment , Baldness , Baldness-treatement , Hair-grow-treatment

Intas launches DCGI-approved Tofacitinib Topical (JAKi) in Auto-Immune Condition Atopic Dermatitis (AD) for Indian patients

Pti: Intas launches DCGI-approved Tofacitinib Topical (JAKi) in Auto-Immune Condition Atopic Dermatitis (AD) for Indian patients

India , Indian-railways , Press-trust-of-india , Intas , Launches , Dcgi , Approved , Tofacitinib , Topical , Jaki , In

Zydus receives final and tentative Approval from the USFDA for Tofacitinib Tablets, 5 mg and 10 mg

Zydus Lifesciences Ltd's subsidiary Zydus Pharmaceuticals USA Inc. has received final approval for Tofacitinib Tablets, 5 mg and tentative approval for Tofacitinib Tablets, 10 mg from the United States Food and Drug Administration.

Ahmedabad , Gujarat , India , United-states , Moraiya , Zydus-pharmaceuticals-united-states-inc , Zydus-lifesciences , Drug-administration , Cadila-healthcare , Tofacitinib-tablets , Lifesciences-limited

Peanut Allergy Treatment for Kids; Myocarditis After COVID Vax

Also in TTHealthWatch: implantable loop recorder for Afib detection and JAK inhibitors in RA

El-paso , Texas , United-states , Rick-lange , Elizabeth-tracey , United-states-preventive-services-task-force , Texas-tech-university-health-sciences-center , Paull-foster-school-of-medicine , Johns-hopkins-medicine , Im-elizabeth-tracey , Im-rick-lange , New-england-journal

Tofacitinib May Cut Colectomy Risk in Hospitalized, Severe UC

Small study found that patients appeared to benefit from limited-duration high-intensity therapy

Ann-arbor , Michigan , United-states , Chicago , Illinois , Jeffreya-berinstein , Zaina-hamza , University-of-michigan , Clinical-gastroenterology , Medpage-today , Tofacitinib , Colectomy

Game Changer for Ulcerative Colitis Patients Failing Anti-TNF?

email article
Treatment with tofacitinib (Xeljanz) proved to be rapidly effective for moderate-to-severe ulcerative colitis (UC), even in patients who previously failed tumor necrosis factor (TNF) inhibition, post hoc analysis of trial data indicated.
While the oral small-molecule JAK inhibitor had greater efficacy than placebo for both induction and maintenance of remission, rates of herpes zoster (serious and non-serious) were numerically higher in tofacitinib recipients, regardless of previous response to TNF inhibition, reported William Sandborn, MD, of the University of California San Diego.
TNF inhibitor failure has been suggested as a predictor of poor prognosis in UC. Patients refractory to this therapy may be more challenging to treat, and therefore have an unmet need for alternative therapies.

United-states , American , William-sandborn , Edward-barnes , Pfizer , University-of-california-san-diego , University-of-north-carolina-at-chapel-hill , American-gastroenterological-association , California-san , Clinical-gastroenterology , North-carolina , Chapel-hill